Document:

COMMITMENT INCREASE AND JOINDER AGREEMENT

 Exhibit 10.2 
 EXECUTION VERSION 
 COMMITMENT INCREASE AND JOINDER AGREEMENT

 THIS COMMITMENT INCREASE AND JOINDER AGREEMENT, dated as of March 30, 2012 (this “Commitment Increase
Agreement”), by and among FIDELITY NATIONAL INFORMATION SERVICES, INC., a Georgia corporation (the “Company”), each lender listed on the signature pages hereto (each, an “Increasing/Joinder Lender”),
JPMORGAN CHASE BANK, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”), Swing Line Lender and L/C Issuer and BANK OF AMERICA, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Swing Line Lenders.

 RECITALS: 
 WHEREAS, reference is hereby made to that certain Third Amended and Restated Credit Agreement, dated as of March 30, 2012, by and among the Company, the Designated Borrowers from time to time
party thereto, each lender from time to time party thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and Bank of America, N.A. and Wells Fargo Bank, National Association, as Swing Line Lenders (as further
amended, amended and restated, supplemented or otherwise modified from time to time the “Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to them in the Credit
Agreement; 
 WHEREAS, pursuant to Section 2.16 of the Credit Agreement, the Company may request additional Term
Commitments and/or additional Revolving Credit Commitments, and may invite existing Lenders and additional Eligible Assignees to become Lenders in respect of such commitments; and 

WHEREAS, the Company has requested that the Increasing/Joinder Lenders make (x) pursuant to Sections 2.16(a)(iii) and
(v) of the Credit Agreement, Additional Term Loans in the form of Term A-3 Loans in an aggregate principal amount of $552,785,748.08 (the “New Term A-3 Commitments”), (y) pursuant to Sections 2.16(a)(iii) and (v) of the
Credit Agreement, Additional Revolving Commitments in the form of 2017 Multicurrency Revolving Credit Commitments in an aggregate amount of $176,767,550.33 (the “New 2017 Multicurrency Revolving Credit Commitments”) and
(z) pursuant to Section 2.16(a)(v) of the Credit Agreement, Additional Revolving Commitments in the form of 2017 US Dollar Revolving Credit Commitments in an aggregate amount of $56,605,000.00 (the “New 2017 US Dollar Revolving
Credit Commitments”, and, together with the New Term A-3 Commitments and the New 2017 Multicurrency Revolving Credit Commitments, the “Additional Commitments”). 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereto hereby agree as follows: 

 Section 1. Aggregate Commitments Increase. On the Additional Commitments
Effective Date (as defined below) and subject to the terms and conditions set forth herein, each Increasing/Joinder Lender party hereto hereby agrees to provide its respective New Term A-3 Commitment and/or Additional Revolving Commitments in the
form of New 2017 Multicurrency Revolving Credit Commitments or New 2017 US Dollar Revolving Credit Commitments, as applicable, as set forth on Schedule A hereto (which amounts shall reflect the amounts of the New Term A-3 Commitment and/or New 2017
Multicurrency Revolving Credit Commitments or New 2017 US Dollar Revolving Credit Commitments allocated to such Increasing/Joinder Lender in the Lead Arrangers’ discretion and, in the aggregate, shall not exceed the aggregate Additional
Commitments that such Increasing/Joinder Lender is willing to provide, as specified on its signature page). For purposes hereof, (i) each Increasing/Joinder Lender with a New Term A-3 Commitment hereunder is referred to as an
“Increasing Term A-3 Lender”, (ii) each Increasing/Joinder Lender with a New 2017 Multicurrency Revolving Credit Commitment is referred to herein as an “Increasing 2017 Multicurrency Revolving Credit Lender”
and (iii) each Increasing/Joinder Lender with a New 2017 US Dollar Revolving Credit Commitment is referred to herein as an “Increasing 2017 US Dollar Revolving Credit Lender”. 

Section 2. Schedule 2.01. As of the Additional Commitments Effective Date and subject to the satisfaction of the conditions
to effectiveness set forth herein, Schedule 2.01 to the Credit Agreement shall be replaced by the form of Schedule 2.01 to this Agreement (which shall reflect the amounts set forth in Schedule A). 

Section 3. Concerning the Additional Term A-3 Loans. (a) Subject to the terms and conditions set forth herein, each
Increasing Term A-3 Lender party hereto severally agrees to make, on the Additional Commitments Effective Date, a single Term A-3 Loan in Dollars to the Company in an amount equal to the commitment amount set forth next to such Increasing/Joinder
Lender’s name in Schedule A hereto under the caption “Additional Term A-3 Commitment” (collectively, the “New Term A-3 Loans”). 
 (b) The terms of the New Term A-3 Loans, including without limitation, the interest rate, amortization payments and maturity date applicable thereto, shall be identical to those set forth in the Credit
Agreement for the Term A-3 Loans. 
 Section 4. Concerning the Additional 2017 Multicurrency Revolving Credit
Commitments. (a) (i) On the Additional Commitments Effective Date, subject to the terms and conditions set forth herein, each of the Lenders with existing Multicurrency Revolving Credit Commitments shall assign to each of the
Increasing 2017 Multicurrency Revolving Credit Lenders, and each of the Increasing 2017 Multicurrency Revolving Credit Lenders shall purchase from each of the Lenders with existing Multicurrency Revolving Credit Commitments, at the principal amount
thereof, such interests in the Outstanding Amount of Multicurrency Revolving Credit Loans on the Additional Commitments Effective Date as shall be necessary in order that after giving effect to all such assignments and purchases, the principal
amount of Multicurrency Revolving Credit Loans made by each Multicurrency Revolving Credit Lender will be in the amount of such Multicurrency Revolving Credit Lender’s Pro Rata Share (after

  
 2 

 
giving effect to the increase in the 2017 Multicurrency Revolving Credit Commitments in accordance with this Commitment Increase Agreement) of the Outstanding Amount of the Multicurrency
Revolving Credit Loans. 
 (ii) If, as a result of the assignment and purchase of the Multicurrency Revolving
Credit Loans provided for in this Section 4(a), any payment of Eurocurrency Rate Loans occurs on a day which is not the last day of the applicable Interest Period, the Company will pay to the Administrative Agent for the benefit of any Multicurrency
Revolving Credit Lender holding a Eurocurrency Rate Loan any loss or cost incurred by such Multicurrency Revolving Credit Lender therefrom in accordance with Section 3.07 of the Credit Agreement. 

(b) Upon the Additional Commitments Effective Date and the assignment and purchase described in Section 4(a), each Increasing 2017
Multicurrency Revolving Credit Lender shall be deemed to have irrevocably and unconditionally purchased and received, without recourse or warranty, an undivided participation in all outstanding Swing Line Loans and Letters of Credit in accordance
with such Increasing 2017 Multicurrency Revolving Credit Lender’s Pro Rata Share thereof (after giving effect to the increase in the 2017 Multicurrency Revolving Credit Commitments in accordance with this Commitment Increase Agreement).

 (c) Each New 2017 Multicurrency Revolving Credit Commitment shall be deemed for all purposes a 2017 Multicurrency Revolving
Credit Commitment and each Loan made thereunder shall be deemed, for all purposes, a 2017 Multicurrency Revolving Credit Loan (the “New 2017 Multicurrency Revolving Credit Loans”). The terms and provisions of the New 2017
Multicurrency Revolving Credit Loans shall be identical to those set forth in the Credit Agreement for the 2017 Multicurrency Revolving Credit Loans. 
 Section 5. Concerning the Additional 2017 US Dollar Revolving Credit Commitments. (a) (i) On the Additional Commitments Effective Date, subject to the terms and conditions set
forth herein, each of the Lenders with existing US Dollar Revolving Credit Commitments shall assign to each of the Increasing 2017 US Dollar Revolving Credit Lenders, and each of the Increasing 2017 US Dollar Revolving Credit Lenders shall purchase
from each of the Lenders with existing US Dollar Revolving Credit Commitments, at the principal amount thereof, such interests in the Outstanding Amount of US Dollar Revolving Credit Loans on the Additional Commitments Effective Date as shall be
necessary in order that after giving effect to all such assignments and purchases, the principal amount of US Dollar Revolving Credit Loans made by each US Dollar Revolving Credit Lender will be in the amount of such US Dollar Revolving Credit
Lender’s Pro Rata Share (after giving effect to the increase in the 2017 US Dollar Revolving Credit Commitments in accordance with this Commitment Increase Agreement) of the Outstanding Amount of the US Dollar Revolving Credit Loans.

 (ii) If, as a result of the assignment and purchase of the US Dollar Revolving Credit Loans provided for in
this Section 5(a), any payment of Eurocurrency Rate Loans occurs on a day which is not the last day of the 

  
 3 

 
applicable Interest Period, the Company will pay to the Administrative Agent for the benefit of any US Dollar Revolving Credit Lender holding a Eurocurrency Rate Loan any loss or cost incurred by
such US Dollar Revolving Credit Lender therefrom in accordance with Section 3.07 of the Credit Agreement. 
 (b) Each New
2017 US Dollar Revolving Credit Commitment shall be deemed for all purposes a 2017 US Dollar Revolving Credit Commitment and each Loan made thereunder shall be deemed, for all purposes, a 2017 US Dollar Revolving Credit Loan (the “New 2017
US Dollar Revolving Credit Loans”). The terms and provisions of the New 2017 US Dollar Revolving Credit Loans shall be identical to those set forth in the Credit Agreement for the 2017 US Dollar Revolving Credit Loans. 

Section 6. New Lenders. (a) To the extent not already a Lender under the Credit Agreement, each Increasing/Joinder
Lender party hereto acknowledges and agrees that upon its execution of this Commitment Increase Agreement and the making of Term A-3 Loans and/or 2017 Multicurrency Revolving Commitments or 2017 US Dollar Revolving Commitments, as applicable, that
such Increasing/Joinder Lender shall become a “Lender” under, and for all purposes of, the Credit Agreement and the other Loan Documents, and shall be subject to and bound by the terms thereof (as modified by the provisions of this
Commitment Increase Agreement), and shall perform all the obligations of and shall have all rights of a Lender thereunder (as modified by the provisions of this Commitment Increase Agreement). 

(b) Each Increasing/Joinder Lender party hereto (i) confirms that it has received a copy of the Credit Agreement, together with
copies of the most recent financial statements delivered pursuant to Sections 6.01(a) and 6.01(b) of the Credit Agreement and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter
into this Commitment Increase Agreement; (ii) agrees that it will, independently and without reliance upon the Administrative Agent or any other Lender or Agent and based on such documents and information as it shall deem appropriate at the
time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes the Administrative Agent to take such action as agent on its behalf and to exercise such powers under the
Credit Agreement and the other Loan Documents as are delegated to the Administrative Agent by the terms thereof, together with such powers as are reasonably incidental thereto; and (iv) agrees that it will perform in accordance with their terms
all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender. 
 (c) Each
Increasing/Joinder Lender represents and warrants that it is an Eligible Assignee. 
 (d) On or prior to the date which is ten
Business Days after the Additional Commitments Effective Date, each Increasing/Joinder Lender that is a Foreign Lender shall deliver to the Administrative Agent such documentation that is required to be delivered by it pursuant to Section 11.16
of the Credit Agreement, duly completed and executed by such Lender. 

  
 4 

 (e) For purposes of the Credit Agreement, the initial notice address of each
Increasing/Joinder Lender party hereto shall be as set forth below its signature below. 
 Section 7. Representations
and Warranties. To induce the other parties hereto to enter into this Commitment Increase Agreement, the Company represents and warrants to each other party hereto that as of the date hereof and as of the Additional Commitments Effective Date:

 (a) The execution, delivery and performance by the Company of this Commitment Increase Agreement are (i) within the
Company’s corporate or other powers, (ii) have been duly authorized by all necessary corporate, shareholder or other organizational action, and (iii) do not and will not (A) contravene the terms of any of the Company’s
Organization Documents, (B) conflict with or result in any breach or contravention of, or the creation of any Lien under (other than as permitted by Section 7.01 of the Credit Agreement), or require any payment to be made under
(1) any documentation governing any Permitted Subordinated Indebtedness, (2) any other Contractual Obligation to which the Company is a party or affecting the Company or the properties of the Company or any of its Subsidiaries or
(3) any order, injunction, writ or decree, of or with any Governmental Authority or any arbitral award to which the Company or its property is subject, or (C) violate, in any material respect, any Law; except with respect to any conflict,
breach or contravention or payment (but not creation of Liens) referred to in clause (B) to the extent that such conflict, breach, contravention or payment could not reasonably be expected to have a Material Adverse Effect. 

(b) This Commitment Increase Agreement has been duly executed and delivered by the Company. This Commitment Increase Agreement
constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other
Laws affecting creditors’ rights generally and by general principles of equity. 
 (c) The representations and warranties
of each Loan Party set forth in Article 5 of the Credit Agreement and in the other Loan Documents that are qualified by materiality are true and correct, and the representations and warranties that are not so qualified are true and correct in all
material respects, in each case on and as of the date hereof (other than with respect to any representation and warranty that expressly relates to an earlier date, in which case such representation and warranty is true and correct in all material
respects as of such earlier date). 
 (d) After giving effect to this Commitment Increase Agreement and the transactions
contemplated hereby, no Default has occurred and is continuing. 
 Section 8. Conditions to Effectiveness of this
Commitment Increase Agreement. The effectiveness of this Commitment Increase Agreement is subject to the satisfaction of the following conditions precedent (the date on which all of such conditions shall first be satisfied, the
“Additional Commitments Effective Date”): 

  
 5 

 (a) The Administrative Agent shall have received counterparts of this Commitment Increase
Agreement executed by the Increasing/Joinder Lenders and the Company. 
 (b) The conditions set forth in Sections 4.02(a) and
(b) of the Credit Agreement shall be satisfied on and as of the Additional Commitments Effective Date, and the Administrative Agent shall have received a certificate dated as of the Additional Commitments Effective Date, and signed by a
Responsible Officer of the Company, to such effect. 
 (c) The Administrative Agent shall have received payment from the
Company, for the account of each Increasing/Joinder Lender that executes and delivers a counterpart signature page to this Commitment Increase Agreement at or prior to 5:00 p.m., New York City time, on March 27, 2012 (or such later time as the
Company shall agree, in its sole discretion), an upfront fee (the “Upfront Fee”) in an amount equal to 1.00% of the aggregate Additional Commitments of such Increasing/Joinder Lender (unless otherwise agreed between the Company and
such Increasing/Joinder Lender). The Upfront Fees shall be payable on the Additional Commitments Effective Date (upon the satisfaction of all other conditions for the occurrence thereof), in immediately available funds and, once paid, such fee or
any part thereof shall not be refundable. 
 Section 9. Governing Law. THIS COMMITMENT
INCREASE AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 
 Section
10. Costs and Expenses. The Company agrees to reimburse the Administrative Agent for its reasonable out-of-pocket expenses in connection with this Commitment Increase Agreement, including the reasonable fees, charges and
disbursements of counsel for the Administrative Agent. 
 Section 11. Counterparts. This Commitment
Increase Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery by facsimile or other electronic imaging means of an executed
counterpart of a signature page to this Commitment Increase Agreement shall be effective as delivery of an original executed counterpart of this Commitment Increase Agreement. 
 Section 12. Headings. Section headings herein are included for convenience of reference only and shall not affect the interpretation of this Commitment Increase Agreement.

 [Remainder of page intentionally blank] 

  
 6 

 IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to
execute and deliver this Commitment Increase Agreement as of the day and year first above written. 
  

			
	[INCREASING/JOINDER LENDERS]
		
	By:	 	[On file with Administrative Agent]
		 	  

		 	Name:
		 	Title:

 
			
	FIDELITY NATIONAL
	      INFORMATION SERVICES, INC.
		
	By:	 	/s/    Kirk T. Larsen
		 	Name: Kirk T. Larsen
		 	Title: Senior Vice President and Treasurer

  

			
	Consented to by:
	
	JPMORGAN CHASE BANK, N.A.,
	as Administrative Agent,
	Swing Line Lender and L/C Issuer
		
	By:	 	/s/    Tina Ruyter
		 	Name: Tina Ruyter
		 	Title: Executive Director

  

			
	BANK OF AMERICA, N.A.,
	as Swing Line Lender
		
	By:	 	/s/    Debra E. DelVecchio
		 	Name: Debra E. DelVecchio
		 	Title: Managing Director

  

			
	WELLS FARGO BANK, NATIONAL
	ASSOCIATION,
	as Swing Line Lender
		
	By:	 	/s/    Tracy L. Moosbrugger
		 	Name: Tracy L. Moosbrugger
		 	Title: Managing Director

 SCHEDULE A 
 (ALL AMOUNTS IN US DOLLARS) 
  

																	
	 Lender
	 	New Term A-3
Commitment	 	    	New 2017
Multicurrency
Revolving Credit
Commitment	 	    	New 2017
US Dollar
Revolving Credit
Commitment	 	    	Total Additional
Commitments	 
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
		 				    				    				    			
	 Total
	 	$	552,785,748.08	  	    	$	176,767,550.33	  	    	$	56,605,000.00	  	    	$	786,158,298.41	  

 Schedule 2.01 

Commitments And Term Loans 
 (ALL FIGURES IN U.S. DOLLARS) 
  

					
	 Class
	  	 Per Lender
	  	Aggregate
	 Term A-2 Commitment
	  	[On file with Administrative Agent]	  	$250,000,000
	 Term A-3 Commitment
	  	[On file with Administrative Agent]	  	$    2,100,000
	 Term B Commitment
	  	[On file with Administrative Agent]	  	$200,000,000
	 2014 US Dollar Revolving Credit Commitment
	  	[On file with Administrative Agent]	  	$                    0
	 2017 US Dollar Revolving Credit Commitment
	  	[On file with Administrative Agent]	  	$200,000,000
	 2014 Multicurrency Revolving Credit Commitment
	  	[On file with Administrative Agent]	  	$                    0
	 2017 Multicurrency Revolving Credit Commitment
	  	[On file with Administrative Agent]	  	$950,000,0003D Bio-Printer Development Program Agreement

 Exhibit 10.26 

 

			
	

	  	Proposal

  
  

Organovo 

Leeloo - Stage 1.4 
 Manufacture and Supply of 3D BioPrinters 
  

 
 [*******] 

Our Ref: OT17860:40790d1 ZLC:csd 
 Issue D

 2 March 2011 
  

 
  

			
		  	

		  	WEST\229688639.1

  
 

 
 EXECUTIVE SUMMARY 
 Organovo is developing a 3D Bio-printer as part of their groundbreaking process to produce tissue engineered constructs for tissue repair and organ replacement. 

Organovo created a proof of principle (POP) printer prototype that they have used to successfully demonstrate the organ-building concept.
They then employed Invetech to develop a more mature Bio-printer to further demonstrate and advance the 3D Bio-printer core technology. Organovo now wish to place additional Bio-printers at partner research laboratory sites to provide them with
printing capability and to enable more rapid maturation of the tissue engineering process and technology. 
 Organovo and
Invetech have highlighted some improvements, which were identified during operation of the first Bio-printer, and will undertake these improvements in conjunction with the Invetech Biomedical Instruments and Development group (BID). 

This Proposal for Stage 1.4 covers the development program to refine the Bio-printer design and the manufacture and supply of four
(4) or six (6) additional Bio Printers to Organovo. It is expected that the outputs of the design activities, including any updates from Organovo, will not impact material cost or build complexity. Also included is an Establishment
activity required to set up manufacturing in our ISO 9001 facility and provide the documented outputs for future manufacturing of Bio-printers. 
 Assuming commencement of first order on or before 7 March 2011, we anticipate completion of the first two BioPrinters by 15 July 2011, the second two BioPrinters by 12 August 2011 and the
remaining two BioPrinters by 14 October 2011. The total budget for Stage 1.4 (inclusive of fees, materials, assembly and testing) is AUD [*******] for the 6 BioPrinter program or AUD [*******] for the 4 BioPrinter program.

  
 

 
 TABLE OF CONTENTS 

 

											
	 	 	 	 	 	 	 	  	Page	 
			
	 1.    
	 	INTRODUCTION	  	 	1	  
				
		 	1.1    	 	Bio-Printer System Description	  	 	1	  
				
		 	1.2	 	Key Manufacturing Issues to be Addressed	  	 	2	  
				
		 	1.3	 	Proposed Development Approach	  	 	2	  
				
		 	1.4	 	Custom Bio-printer Configurations	  	 	2	  
			
	2.	 	THE PROPOSED PROGRAM	  	 	3	  
				
		 	2.1	 	Stage Objectives	  	 	3	  
				
		 	2.2	 	Program of Work	  	 	3	  
				
		 	2.3	 	Invetech Outputs	  	 	7	  
				
		 	2.4	 	Organovo Inputs	  	 	8	  
			
	3.	 	BUDGET AND TIMESCALE	  	 	8	  
				
		 	3.1	 	Option A: Budget Allocation for 4 BioPrinter Program	  	 	8	  
				
		 	3.2	 	Option B: Budget Allocation for 6 BioPrinter Program	  	 	9	  
				
		 	3.3	 	Timescale	  	 	10	  
				
		 	3.4	 	Invoicing Schedule	  	 	10	  
					
		 		 	3.4.1    	 	Invoice Schedule for 4 BioPrinter Program	  	 	10	  
					
		 		 	3.4.2	 	Invoice Schedule for 6 BioPrinter Program	  	 	11	  
				
		 	3.5	 	Shipping Schedule	  	 	11	  
					
		 		 	3.5.1	 	Shipping Schedule for 4 BioPrinter Program	  	 	11	  
					
		 		 	3.5.2	 	Shipping Schedule for 6 BioPrinter Program	  	 	11	  
				
		 	3.6	 	Budget, Timescale and Invoicing Notes	  	 	11	  
			
	4.	 	TERMS OF BUSINESS	  	 	12	  
			
	5.	 	ASSIGNMENT AUTHORIZATION	  	 	12	  
		
	APPENDIX A - SUPPORTING NOTES	  			
			
		 	Intellectual Property	  			
			
		 	Budget, Timescale and Invoicing	  			

	1.	INTRODUCTION 

  

	 	1.1	Bio-Printer System Description 

 The system is comprised of two major components: the Bio-printer, and the control PC. The BioPrinter is designed to operate inside a BSC (bio-safety cabinet), while the control PC sits outside of the
clean environment. All further references to the “Bio-printer” in this document refer to the combined PC and robotics system. 
  

 
 [*******] 
 Figure 2 – BioPrinter Robotics and Functional Sub-systems 

  

	 	1.2	Key Manufacturing Issues to be Addressed 

 Key issues to be addressed in stage 1.4 are: 
 1. Accurate
alignment of design documentation with the January 2011 BioPrinter configuration and implementation of key improvements. 
 2. Provide effective transition from development activities into manufacturing whilst keeping to the agreed schedule 

3. To provide a fast introduction of the BioPrinters to structured ISO 9001 manufacturing 

 

	 	1.3	Proposed Development Approach 

 During Stage 1.1, Invetech focused on the design and supply of an initial BioPrinter to allow Organovo to demonstrate the core printer technology in a more automated format. 

During Stage 1.2, Invetech focused on key software improvements. 

During Stage 1.3, Invetech completed some loom design improvements. 

During Stage 1.4, Invetech will focus on updating the hardware design to match the BioPrinter produced in Stage 1.1 including
the loom design updates from Stage 1.3. Invetech will then replicate the BioPrinters based on the updated, agreed configuration. 
 Further development stages will be undertaken dependant upon the progress of the BioPrinter development program and Organovo’s market strategy for the development of the system for manufacture.

  

	 	1.4	Custom Bio-printer Configurations 

 Organovo has advised the possibility of Bio-printer customization based on the individual laboratory requirements of customers. Invetech will manage these changes, on a case by case basis, using the CCR
(Client Change Request) system to accommodate variations in instrument configuration and expenditure. 
 This proposal outlines
the materials and fee costs for a “base configuration” as agreed at completion of the enclosed development activities. Any deviations from this will be covered by a separate CCR for each unit and will detail the following: 

 

	 	•	 	 Any investigation/development effort required to action the changes 

 

	 	•	 	 Any procurement/material cost deviations to add/remove components 

 

	 	•	 	 Any implementation costs associated with assembly or testing. 

  
 2 

 Each CCR is allocated a unique document number and is revision controlled. Invetech will
respond to each CCR with an estimate of the fees and expenses required to incorporate the deviations. The final version is to be approved by Organovo prior to commencement of the proposed activities. 

 

	2.	THE PROPOSED PROGRAM 

  

	 	2.1	Stage Objectives 

 The
objectives of this Stage 1.4 program is to provide Organovo, Inc with 
  

	 	•	 	 An updated Bio-printer configuration from Stage 1.1 which incorporates the requested design updates listed in section 2.2

  

	 	•	 	 Establish basic procedures to build additional Bio-Printers for future small volume manufacturing 

 

	 	•	 	 An additional four (4) or six (6) upgraded Bio-Printers for sale or lease to partner research laboratories 

* Note:    This Stage 1.4 covers BioPrinter refinement and build activities only. The development or
manufacturing process followed will not be in accordance with ISO 13485 or FDA and QSR requirements. 
  

	 	2.2	Program of Work 

 To
achieve our objective(s), Invetech will carry out the following tasks in this assignment: 
  

			
	A.	  	[*******]

  
 3 

			
	B.	  	 Manufacturing Preparation
  

On authorization of Stage 1.4, hold a start-up meeting with key members of the Organovo team via teleconference (supported by WebEx for document
exchange and review).
  
 The meeting will acquaint the Organovo and Invetech
manufacturing teams, and review the proposed program of work, key schedule milestones and any critical inputs required from Organovo.
  

Review the Bill of Materials, Test Procedures and other data-pack outputs and confirm any manufacturing or testing updates required for the BioPrinter
replication. Generate and review an Updated Bill of Materials as the basis for the BioPrinter replication.

		  	  
 Generate Draft Assembly Instructions to assist
manufacture both for this activity and for possible future manufacturing proposals. The Draft Assembly Instructions will be a combination of written instructions, exported CAD images, photographs and hand written comments to provide minimum
level of instruction required for both this and future build activities.
  

The assembly documentation will be based on the most recently available CAD package outputs.

 
 Generate a Pre-Shipment Qualification Test Plan, that defines final product
release criteria, based on the previously agreed and documented LeeLoo outputs:
  
 •   1055_A3_Test Bed Design Description.doc
  

•   1099_A1_Test Bed Commissioning Overview.doc

 
 •   1056_C1_Test Bed
Design Features.xls
  
 Note:    Invetech has based
the current pre-shipment test and qualification on the current BioPrinter procedures. If the updated procedures vary significantly from the current practice then additional budget will be required.

 
 Setup predefined laboratory and build area for assembly, testing and quarantine of
build components. Acquire Transparent Displacement Sensor and Amplifier equipment in readiness for capillary calibration.
  

	C.	  	[*******]

  
 4 

			
	D.	  	 Build, Test and Pack Bio-Printers
  

Procure and manufacture the wiring harnesses for the BioPrinter build based on the previous design update activities. The outputs of these activities from
proposal OT17941_40759b1 have been reviewed by Invetech and are acceptable for use in this proposed replication activity.

		  	  
 Assemble the OEM and custom components to build the first
BioPrinter according to the assembly documentation above. Conduct power-up, alignment and functional testing according to the agreed test documentation. Confirm the function of the BioPrinter meets all acceptance criteria specified in the test
procedures and update any process documentation as necessary.

		  	  
 Assemble and test the remaining BioPrinters according to the
revised assembly and test documentation. Software release from Stage 1.2 (revision 0.1.4) to be used for this BioPrinter build program.
  

Generate a Pre-Shipment Qualification Test Report for each unit prior to release for shipping to Organovo. This will include an Equipment Safety
review and signoff for each BioPrinter.
  
 Ensure all records of test
documents are approved and packaged with BioPrinters.

		  	  
 Pack and ship the BioPrinters to Organovo’s San Diego
facility (or Organovo nominated site).
  

Note:    Freight allocation (AUD$1,100 per Bio Printer of two cases) is included based on shipping all units together DDU to San
Diego. Detailed air-freight costs (including insurance but not customs duties) are pending formal quotes and will be based on using Organovo supplied custom shipping cases (2 cases required per BioPrinter system). Any costs beyond the current
allocation will be covered in an extension to this Proposal. The shipping crates are rigid, reusable containers however a shipping test has not been included.
  

Update the design documentation (Draft Assembly Instructions, Test Procedures and Bill of Materials) during the manufacturing process
to ensure a refined production process.

  
 5 

			
	 E.
	  	 Manage Manufacturing Activities

 
 Manage the Invetech team to achieve manufacturing objectives; monitoring budget and
schedule to targets.
  
 Maintain effective communications between Invetech
and Organovo by way of Fortnightly Teleconferences and Weekly Progress Reports. Update Invetech Test Track and Organovo with defects and issues arising during BioPrinter build and testing and to capture new design ideas for future
BioPrinter revisions.
  
 Provide an updated Bill of Materials (BOM) and
BioPrinter replication estimate for future BioPrinter manufacturing.
  

Note:    If the stage schedule is delayed due to unforeseen circumstances beyond the planned end date, progress meetings may be
delayed in an effort to help manage development costs.
  
 Prepare an
End-of-stage Acceptance Plan for sign-off on stage completion and work with your team to prepare the next stage Proposal (eg for additional BioPrinter replication, if required). The End of Stage Acceptance Plan will include a FAT (factory acceptance
test) and its sign off approval from Organovo staff at the Invetech site for the first BioPrinter. The agreed FAT effort required will be representative of the effort required to complete the testing currently planned and described in 99_A1_Test Bed
Commissioning Overview.doc as outlined in section 2.2.B. Note: Travel and expenses for Organovo staff to visit Invetech will be at Organovo’s expense.

  
 6 

	 	2.3	Invetech Outputs 

Invetech will generate the following outputs from our Stage 1.4 Program of Work: 

 

			
	 1.
  
 2.
	  	 Updated Design Management Documents
  

a)      Technical Review Minutes

 

b)      Updated Bill of Materials

 

c)      [*******]

 
 d)      Draft
Assembly Instructions
  

e)      Test Procedures

 

f)      Pre-Shipment Qualification Test Plan

 

g)      Pre-Shipment Qualification Test Report

 

h)      Electrical Safety Review Report

		
	 3.
  
 4.
	  	 Hardware Outputs
  

a)      Four (4) or Six (6) BioPrinters including PC and
cabling.
  

b)      Transparent Displacement Sensor and Amplifier for calibration (to be
retained at Invetech for future orders)

		
	 5.
  
 6.
  

7.
	  	 Program Management Documents
  

Updates of program control documents and outputs, as these are refined:
  

a)      Teleconference Meeting Minutes

 

b)      Progress Reports

 

c)      End-of-stage Acceptance Plan and Proposal for next
stage

  
 7 

	 	2.4	Organovo Inputs 

 The
following Organovo inputs will assist Invetech with the above Program of Work. 
  

			
	A.	  	 Preparation
  

To ensure that the System meets requirements and addresses the real market needs, Organovo will need to provide Invetech with any updates of:

 

i)       Bill of materials resulting from design updates in design stage, from
both Organovo and Invetech activities
  
 ii)     Updated test procedures based on latest Organovo refinements (including new Capillary Calibration procedure)

 
 iii)    Preferred
locations for robot opto sensor placement
  
 iv)    Updated Temperature Controller and Calibration Sensor Configuration files (if required for pre-shipment testing)

		
	B.	  	[*******]
		
	C.	  	 Intellectual Property Assessment
  

As part of this System manufacturing program Organovo will periodically review System intellectual property issues with Invetech and work with Organovo
patent attorneys to:
  

i)       identify and advise Invetech of patents that may constrain System
design concepts
  

ii)     identify potential infringement risks

 
 iii)    take any steps
deemed appropriate to protect new intellectual property that may be generated as part of this assignment.

  

	3.	BUDGET AND TIMESCALE 

  

	 	3.1	Option A: Budget Allocation for 4 BioPrinter Program 

 The budget allocation for design updates and manufacturing preparation activities and the supply of four (4) Bio-Printers to Organovo. 

  
 8 

									
	 Design Update Activities
	   

	 Development Activities (Fees and Materials)
	  	 	AUD	  	  	 	[*******]	  
	 Manufacturing Preparation and Management
	  				  			
	 Manufacturing Preparation (Fees)
	  	 	AUD	  	  	 	[*******]	  
	 Materials and Expenses (Manufacturing Preparation)
	  	 	AUD	  	  	 	[*******]	  
	 Planning and Project Management
	  	 	AUD	  	  	 	[*******]	  
	 Build and Test 4 Bio-Printers
	  				  			
	 Part Procurement and Qualification (Fees)
	  	 	AUD	  	  	 	[*******]	  
	 Materials and Expenses (4 units)
	  	 	AUD	  	  	 	[*******]	  
	 Assembly, Testing and Packing
	  	 	AUD	  	  	 	[*******]	  
	 Management Reserve
	  	 	AUD	  	  	 	[*******]	  
		  	  
	  
	 	  	  
	  
	 
	 Total costs
	  	 	AUD	  	  	 	[*******]	  
		  	  
	  
	 	  	  
	  
	 

  

	 	•	 	 Total cost per Bio-Printer (excluding design update activities) is AUD [*******] 

Notes 
  

	 	•	 	 Expenditures in the above table are inclusive of fees, materials and expenses. 

 

	 	•	 	 As development work progresses, actual expenditures may be varied from the above allocations, within total budget constraints.

  

	 	3.2	Option B: Budget Allocation for 6 BioPrinter Program 

 The budget allocation for design updates and manufacturing preparation activities and the supply of six (6) Bio-Printers to Organovo. 

 

									
	 Design Update Activities
	   

	 Development Activities (Fees and Materials)
	  	 	AUD	  	  	 	[*******]	  
	 Manufacturing Preparation and Management
	  				  			
	 Manufacturing Preparation (Fees)
	  	 	AUD	  	  	 	[*******]	  
	 Materials and Expenses (Manufacturing Preparation)
	  	 	AUD	  	  	 	[*******]	  
	 Planning and Project Management
	  	 	AUD	  	  	 	[*******]	  
	 Build and Test 6 Bio-Printers
	  				  			
	 Part Procurement and Qualification (Fees)
	  	 	AUD	  	  	 	[*******]	  
	 Materials and Expenses (6 units)
	  	 	AUD	  	  	 	[*******]	  
	 Assembly, Testing and Packing
	  	 	AUD	  	  	 	[*******]	  
	 Management Reserve
	  	 	AUD	  	  	 	[*******]	  
		  	  
	  
	 	  	  
	  
	 
	 Total costs
	  	 	AUD	  	  	 	[*******]	  
		  	  
	  
	 	  	  
	  
	 

 Total cost per Bio-Printer (excluding design update activities) is AUD [*******] 

Notes 

  
 9 

	 	•	 	 Expenditures in the above table are inclusive of fees, materials and expenses. 

 

	 	•	 	 As development work progresses, actual expenditures may be varied from the above allocations, within total budget constraints.

  

	 	3.3	Timescale 

 The
procurement and manufacturing team is currently available to commence work now. To ensure timely delivery of the BioPrinters upon proposal authorization, it is recommended the longer lead-time items (OEM Axes, PC) purchasing is commenced as soon as
possible. 
 Assuming receipt of Organovo’s Authorization to commence work on or before 7 March 2011, we estimate that
completion of the first two BioPrinters by 15 July 2011, the next two by 12 August 2011, and the remaining two Bio-Printers by 14 October 2011. These dates are based on previous investigation by Invetech and Organovo on the difficult
to source components. We have assumed procurement of these long-lead items (eg Danaher rails) do not impact the above schedule and Invetech will remain committed to meeting the expected schedule. 

The estimated lead-time for future bio-printer orders is at least 26 weeks and is based on previously quoted delivery schedules for the
key long lead items (eg. stepper cards, Danaher motion axes and thermo cooler). 
  

	 	3.4	Invoicing Schedule 

 For
Stage 1.4 of the program, Invetech will invoice Organovo on the following payment schedule. 
  

	 	3.4.1	Invoice Schedule for 4 BioPrinter Program 

  

									
	 Invoice Reference
	  	Amount (AUD)	 	  	Invoice Date	 
	 1.3.1 Authorization received
	  	 	[*******]	  	  	 
  
	7 March 2011

(indicative
	  
 ) 

			
	 1.3.2 Progress Payment
	  	 	[*******]	  	  	 	8 April 2011	  
			
	 1.3.3 BioPrinters 1-2 Complete
	  	 	[*******]	  	  	 	15 July 2011	  
			
	 1.3.4 BioPrinters 3-4 Complete
	  	 	[*******]	  	  	 	12 August 2011	  
		  	  
	  
	 	  			
			
	 Total
	  	 	AUD [*******]	  	  			
		  	  
	  
	 	  			

  
 10 

	 	3.4.2	Invoice Schedule for 6 BioPrinter Program 

  

									
	 Invoice Reference
	  	Amount (AUD)	 	  	Invoice Date	 
	 1.3.1 Authorization received
	  	 	[*******]	  	  	 
  
	7 March 2011

(indicative
	  
 ) 

			
	 1.3.2 Progress Payment
	  	 	[*******]	  	  	 	8 April 2011	  
			
	 1.3.3 BioPrinters 1-2 Complete
	  	 	[*******]	  	  	 	15 July 2011	  
			
	 1.3.4 BioPrinters 3-4 Complete
	  	 	[*******]	  	  	 	12 August 2011	  
			
	 1.3.5 BioPrinters 5-6 Complete
	  	 	[*******]	  	  	 	14 October 2011	  
		  	  
	  
	 	  			
			
	 Total
	  	 	AUD [*******]	  	  			
		  	  
	  
	 	  			

  

	 	3.5	Shipping Schedule 

  

	 	3.5.1	Shipping Schedule for 4 BioPrinter Program 

The following table is the expected shipping schedule for the 4 BioPrinter Program 

 

					
	 Instrument Number
	  	Indicative Shipment Date	 
	 Bio-Printers 1 and 2

 
 Bio-Printers 3 and 4
	  	   

 
	15 July 2011  

12 August 2011
	    
   

  

	 	3.5.2	Shipping Schedule for 6 BioPrinter Program 

 The following table is the expected shipping schedule for the 6 BioPrinter Program 
  

					
	 Instrument Number
	  	Indicative Shipment Date	 
	 Bio-Printers 1 and 2

 
 Bio-Printers 3 and 4

 
 Bio-Printers 5 and 6
	  	   

 
  
  
	15 July 2011  

12 August 2011
  

14 October 2011
	    
   
  

  

  

	 	3.6	Budget, Timescale and Invoicing Notes 

 a) The first scheduled payment will be invoiced on, and is payable by Organovo immediately upon, receipt of Organovo authorization and is subject to the Terms of Business appended. 

b) The last invoice will only be due for payment following Organovo sign-off on Stage 1.4 completion (as defined in
the mutually agreed End-of-stage Acceptance Plan), the date of sign-off on Stage completion being the Termination Date. 
 c) The total budget for the Program of Work defined in Section 3.1 is firm to within plus 10%. If additional effort and expense (within this plus 10% limit) is required to complete this work, then
Invetech will seek your written approval prior to invoicing. 

  
 11 

 d) If additional Budget (under Section 3.1) is required due to changes
in Objectives (Section 2.1), Program of Work (Section 2.2), Outputs (Section 0) or Client Inputs (Section 2.4), then Invetech will document this in an extension Proposal. Budget (and associated invoicing) will only be increased
following Organovo authorization of this extension Proposal. 
 e) The above budget includes allowance for
materials and expenses (including but not limited to Bio-Printer, prototypes, software and hardware purchases, production aids and equipment, communication, travel and subsistence, and general disbursements) with an 18 per cent handling and
profit mark-up. 
 f) Details of any Invetech expenditure on production tooling, production assembly aids and
production testers will be mutually agreed upon with you at the appropriate time. Such decisions will be based on optimizing the balance between capital cost, part/assembly cost, lead time and aesthetic parameters, and thus Invetech cannot
necessarily guarantee the 10% limit, as defined in (c) above, on these items. 
 g) With the exception of
the first schedule payment, invoices are due for payment within 30 days of date of invoice, in accordance with the attached Terms of Business. 
 h) The above estimate remains valid for 45 days from the date of this document, after which time we reserve the right to revise our offer. 

Please refer to APPENDIX A - SUPPORTING NOTES for additional budget, timescale and invoicing notes.

  

	 	4.	TERMS OF BUSINESS 

 The
Terms of Business applicable to this assignment, including notes on budget, timescale and invoicing, are as previously defined and agreed in Proposal OT17366, Issue E, of 5 May 2009. 

 

	 	5.	ASSIGNMENT AUTHORIZATION 

To authorize the commencement of the proposed assignment, please complete, sign and return the attached “Proposal Authorization”
form. 

  
 12 

 The above invoicing schedule for Stage 1.4 will be followed on your authorization of
this Proposal. 
  

			
	

	  	

	 [*******]
 Program
Manager
	  	 [*******]
 Director Contract
Manufacturing

 This Proposal has been composed specifically in response to a request from Organovo. It remains the
property of Invetech Pry Ltd (ABN 45 004 301 839) until such time as a formal contract for a project is finalized. The contents may not meanwhile be disclosed by Organovo to any third party, nor may any original concepts devised by Invetech Pty Ltd
(ABN 45 004 301 839) for inclusion therein be meanwhile commercially exploited by Organovo. 

  
 13 

  
 

 
 PROPOSAL AUTHORIZATION FORM 
 [*******]  
 Invetech Pty Ltd 
 ABN 45 004 301 839 
 495 Blackburn Road 
 Mt Waverley Victoria 
 Australia 3149 

			
	Telephone:	 	61 3 9211 7700
	Facsimile:	 	61 3 9211 7701
	Facsimile:	 	61 3 9211 7702

  

			
	Re:	  	Leeloo - Stage 1.4
		  	Manufacture and Supply of 3D BioPrinters

 We have read your Proposal OT17860:40790d1 ZLC:csd dated 2 March 2011 and the Terms of Business
referred to in Section 4. 
 We hereby accept your Proposal for (please select): 

 

	 	 ̈	Four (4) BioPrinter design updates and replication (AUD [*******]) 

 

	 	 ̈	Six (6) BioPrinter design updates and replication (AUD [*******]) 

 We hereby authorize you to proceed with the assignment described in this Proposal, and we agree to be bound by the Terms of Business referred to in Section 4. 

 

	
	Signed: /s/ Keith Murphy
	
	Title: Chief Executive Officer
	
	Company:
	Organovo
	
	Date: March 3, 2011

 APPENDIX A - SUPPORTING NOTES 

[*******]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]